R&D News | pharmaphorum

News

AZ may spin off its Chinese business, says report

AstraZeneca is looking at spinning out its Chinese operation and listing it in Hong Kong or Shanghai to insulate the business from rising geopolitical tension, according t

News

Rani’s ‘robotic’ pill delivers injectable osteoporosis drug

US biotech Rani Therapeutics has shown that its oral formulation of a drug for osteoporosis that currently has to be delivered by injection worked as hoped in a first-in-h

News

Biomarker for aggressive fibrotic tumours gets FDA backing

A blood test in development that may be able to predict whether a solid tumour will be particularly aggressive has been given the support of the FDA.

News

Astellas extends protein degrader drive with Cullgen deal

Astellas has become the latest big pharma to pledge big bucks to a smaller company working on protein degraders, paying $35 million upfront to partner with US start-up Cul

News

Amgen names Moderna’s Paul Burton as its new CMO

Amgen has appointed a new chief medical officer, enticing Paul Burton away from Moderna, where he has held the CMO role for nearly two years.

News

Trial of 2seventy bio’s AML cell therapy paused after fatali...

Shares in 2seventy bio were on the slide this morning after the US biotech said Seattle Children’s Therapeutics had paused a clinical trial of its T-cell therapy for acute

AZ may spin off its Chinese business, says report

Rani’s ‘robotic’ pill delivers injectable osteoporosis drug

Biomarker for aggressive fibrotic tumours gets FDA backing

Astellas extends protein degrader drive with Cullgen deal

Amgen names Moderna’s Paul Burton as its new CMO

Trial of 2seventy bio’s AML cell therapy paused after fatali...

Lilly partners with Hims & Hers on obesity drug sales

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks